Rob Mettelman
@rmettelman.bsky.social
SJCRH Postdoc | Thomas Lab | T cell Immunity | Influenza | Virus Enthusiast | Incoming Asst Prof, Pitt CVR | New Dad
Reposted by Rob Mettelman
FLC is a rare, aggressive liver cancer lacking effective systemic therapies. Our vaccine targets the recurrent DNAJB1::PRKACA fusion, offering a universal neoantigen to drive anti-tumor immunity. www.nature.com/articles/s41...
A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial - Nature Medicine
In this phase 1 trial, treatment of patients with fibrolamellar hepatocellular carcinoma with a therapeutic peptide vaccine targeting the fusion kinase DNAJB1–PRKACA, which is the driver of the diseas...
www.nature.com
November 24, 2025 at 9:38 PM
FLC is a rare, aggressive liver cancer lacking effective systemic therapies. Our vaccine targets the recurrent DNAJB1::PRKACA fusion, offering a universal neoantigen to drive anti-tumor immunity. www.nature.com/articles/s41...